1
|
Rullo V, Castellaneta F, D’Antonio S, De Rosa A, Grieco MP, Fabrizio T. Electrochemotherapy in Kaposi's Sarcoma Patients: From the Gold Standard Strategy to Locally Advanced Cutaneous and Subcutaneous Lesions. Cancers (Basel) 2024; 16:1295. [PMID: 38610972 PMCID: PMC11010848 DOI: 10.3390/cancers16071295] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2024] [Revised: 03/16/2024] [Accepted: 03/25/2024] [Indexed: 04/14/2024] Open
Abstract
Electrochemotherapy (ECT) is one of the newest therapeutic strategies employed as a medical procedure for skin neoplasms' treatment, especially for classic Kaposi's sarcoma (CKS). The aim of this study was to demonstrate ECT clinical response and the local control of CKS disease. The primary endpoint was to value the worth and efficacy of this local therapy in CKS skin lesions' treatment. In total, 19 CKS patients were enrolled, 14 males and 5 females with median age at diagnosis of 72. Complete response (CR) has been gained in 12 patients after first ECT attempt; meanwhile, 3 and 4 out of 19 patients obtained a partial response (PR), so they underwent a second and third ECT treatment, respectively. Clinical response was evaluated during the entire timeframe of the follow-up, which ranged between 3 months and 4 years with a median of 18 months. The control of CKS skin lesions still represents a challenge for surgeons and oncologists. Nevertheless, according to this and other authors' recent experiences, ECT could be considered the gold standard strategy for early-stage patients, but at the same time it could be considered as a valid option in controlling Kaposi's sarcoma locally advanced lesions.
Collapse
Affiliation(s)
- Vincenzo Rullo
- Division of Plastic Surgery, IRCCS-Centro di riferimento Oncologico della Basilicata, Via Padre Pio, 1, 95098 Rionero in Vulture, Italy; (V.R.); (F.C.); (S.D.); (A.D.R.); (M.P.G.)
- Division of Plastic Surgery, AOU Federico II, Via S. Pansini, 5, 80131 Naples, Italy
| | - Francesco Castellaneta
- Division of Plastic Surgery, IRCCS-Centro di riferimento Oncologico della Basilicata, Via Padre Pio, 1, 95098 Rionero in Vulture, Italy; (V.R.); (F.C.); (S.D.); (A.D.R.); (M.P.G.)
| | - Santolo D’Antonio
- Division of Plastic Surgery, IRCCS-Centro di riferimento Oncologico della Basilicata, Via Padre Pio, 1, 95098 Rionero in Vulture, Italy; (V.R.); (F.C.); (S.D.); (A.D.R.); (M.P.G.)
- Division of Plastic Surgery, AOU Federico II, Via S. Pansini, 5, 80131 Naples, Italy
| | - Anna De Rosa
- Division of Plastic Surgery, IRCCS-Centro di riferimento Oncologico della Basilicata, Via Padre Pio, 1, 95098 Rionero in Vulture, Italy; (V.R.); (F.C.); (S.D.); (A.D.R.); (M.P.G.)
- Division of Plastic Surgery, AOU Federico II, Via S. Pansini, 5, 80131 Naples, Italy
| | - Michele Pio Grieco
- Division of Plastic Surgery, IRCCS-Centro di riferimento Oncologico della Basilicata, Via Padre Pio, 1, 95098 Rionero in Vulture, Italy; (V.R.); (F.C.); (S.D.); (A.D.R.); (M.P.G.)
| | - Tommaso Fabrizio
- Division of Plastic Surgery, IRCCS-Centro di riferimento Oncologico della Basilicata, Via Padre Pio, 1, 95098 Rionero in Vulture, Italy; (V.R.); (F.C.); (S.D.); (A.D.R.); (M.P.G.)
| |
Collapse
|
2
|
Primary multinodular oral Kaposi's sarcoma – HIV seronegative young patient: Report of a case. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY MEDICINE AND PATHOLOGY 2015. [DOI: 10.1016/j.ajoms.2014.10.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
3
|
Kaposi sarcoma: review and medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol 2012; 113:2-16. [DOI: 10.1016/j.tripleo.2011.05.011] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2011] [Revised: 05/11/2011] [Accepted: 05/15/2011] [Indexed: 12/21/2022]
|
4
|
Wani GM, Ahmad SM, Qayoom S, Khursheed B, Khan AR. Corticosteroid Induced, HHV-8 Positive Kaposi's Sarcoma in a Non-HIV Elderly Patient. THE JOURNAL OF IMA 2012; 44:jima-44-1-09317. [PMID: 23864989 PMCID: PMC3708632 DOI: 10.5915/44-1-9317] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/03/2022]
Abstract
Kaposi’s sarcoma (KS) was first described in 1872 by Moritz Kaposi. In 1994, Chang et al. first identified DNA sequences corresponding to human herpesvirus-8 (HHV-8) in AIDS-associated Kaposi sarcoma biopsies. It is now believed that presence of HHV-8 is necessary but not sufficient to cause KS. Other factors like immunosuppressive therapy also play a role. We describe an HIV-negative elderly patient who developed KS of skin and mucous membrane after prolonged use of corticosteroids for knee pain. The patient was positive for HHV-8.
Collapse
Affiliation(s)
- Gh Mohiuddin Wani
- Department of Dermatology, Venereology and Leprosy Sheri-Kashmir Institute of Medical Sciences (SKIMS)
| | | | | | | | | |
Collapse
|
5
|
Kim SY, Kim DH, Lee HJ, Seo YJ, Lee JH, Lee Y. Treatment of Disseminated Classic Type of Kaposi's Sarcoma with Paclitaxel. Ann Dermatol 2011; 23:504-7. [PMID: 22148021 PMCID: PMC3229947 DOI: 10.5021/ad.2011.23.4.504] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2010] [Revised: 12/06/2010] [Accepted: 12/06/2010] [Indexed: 11/22/2022] Open
Abstract
Classic Kaposi sarcoma (KS) is a rare human herpes virus 8-associated angioproliferative disease, and the disseminated classic type of KS in Korea is even rarer. The treatment options for classic KS vary and range from surgical excision to ionizing irradiation or chemotherapy. Recently, there have been a few reports of treating classic KS with paclitaxel, which has been used to treat AIDS-associated KS and post-transplant KS. We herein report a case of disseminated classic type KS in a 78-year-old Korean male patient who showed dramatic response after only two cycles of paclitaxel treatment.
Collapse
Affiliation(s)
- Soo Yeon Kim
- Department of Dermatology, Chungnam National University College of Medicine, Daejeon, Korea
| | | | | | | | | | | |
Collapse
|
6
|
Curatolo P, Quaglino P, Marenco F, Mancini M, Nardò T, Mortera C, Rotunno R, Calvieri S, Bernengo MG. Electrochemotherapy in the treatment of Kaposi sarcoma cutaneous lesions: a two-center prospective phase II trial. Ann Surg Oncol 2011; 19:192-8. [PMID: 21822561 DOI: 10.1245/s10434-011-1860-7] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2011] [Indexed: 12/11/2022]
Abstract
BACKGROUND Electrochemotherapy (ECT) is an emerging treatment for cutaneous lesions of different tumor types. The combination of chemotherapy and electroporation enhances drug uptake into tumoral cells. However, its role in the treatment of Kaposi sarcoma (KS) has not yet been well defined, and to date, literature reports are scarce. We prospectively evaluated clinical activity and safety of ECT in KS patients. METHODS Twenty-three patients with histologically confirmed unresectable KS, not treatable by radiotherapy or intralesional vincristine therapy, were enrolled onto the study according to the European Standard Operating Procedures of Electrochemotherapy (ESOPE) guidelines and treated with a pulse generator. RESULTS A response to the first ECT session was obtained in all patients, with a complete response (CR) in 14 (60.9%) of 23 patients. A second ECT was performed in 5 (21.7%) and a third in 2, with a median interval between two sessions of 5.1 (range 2.5-25.5) months. Overall, a total of 15 patients (65%) experienced a CR. After a median follow-up of 1.5 years (range 2 months to 4.2 years), 16 patients maintained the response, 4 after repeated courses. Sustained local control of treated lesions was present in 20 of 23 patients. The overall survival rate was 74.4% at 2 years. CONCLUSIONS ECT represents an additional therapeutic tool for the management of KS cutaneous lesions, characterized by a definite clinical activity and long-lasting remissions. The absence of systemic side effects and the low impact on the immune system also make this treatment suitable for elderly people, even with repeated courses.
Collapse
Affiliation(s)
- Pietro Curatolo
- Department of Dermatology and Plastic Surgery, Dermatologic Clinic, University of Rome La Sapienza, Rome, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
7
|
|
8
|
Brambilla L, Bellinvia M, Tourlaki A, Scoppio B, Gaiani F, Boneschi V. Intralesional vincristine as first-line therapy for nodular lesions in classic Kaposi sarcoma: a prospective study in 151 patients. Br J Dermatol 2009; 162:854-9. [DOI: 10.1111/j.1365-2133.2009.09601.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
9
|
The simultaneous diagnosis of Kaposi sarcoma and MDS RAEB-II in a human immunodeficiency virus-negative patient. Ann Hematol 2009; 88:389-91. [DOI: 10.1007/s00277-008-0592-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2008] [Accepted: 08/04/2008] [Indexed: 10/21/2022]
|
10
|
Patrikidou A, Vahtsevanos K, Charalambidou M, Valeri RM, Xirou P, Antoniades K. Non-AIDS Kaposi's sarcoma in the head and neck area. Head Neck 2009; 31:260-8. [DOI: 10.1002/hed.20945] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
11
|
Defail AJ, Edington HD, Matthews S, Lee WCC, Marra KG. Controlled release of bioactive doxorubicin from microspheres embedded within gelatin scaffolds. J Biomed Mater Res A 2006; 79:954-62. [PMID: 16941588 DOI: 10.1002/jbm.a.30865] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
We have encapsulated the chemotherapeutic agent doxorubicin into biodegradable polymer microspheres, and incorporated these microspheres into gelatin scaffolds, resulting in a controlled delivery system. Doxorubicin was encapsulated in poly(D,L-lactide-co-glycolide) (PLGA) using a double emulsion/solvent extraction method. Characterization of the microspheres including diameter, surface morphology, and in vitro drug release was determined. The release of doxorubicin up to 30 days in phosphate buffered solution was assessed by measuring the absorbance of the releasate solution. Gelatin scaffolds were crosslinked using glutaraldehyde and microspheres were added to gelatin during gelation. The murine mammary mouse tumor cell line, 4T1, was treated with various doses of doxorubicin. A propidium iodide assay was utilized to visualize dead cells. Using a Transwell basket assay, PLGA microspheres and gelatin constructs were suspended above 4T1 cells for 48 h. Viable cells were determined using the CyQUANT cell proliferation assay. Results indicate that the release was controlled by the incorporation of PLGA microspheres into gelatin constructs. A significant difference was seen in the cumulative release over days 5-16 (p < 0.05). The bioactivity of doxorubicin released from the microspheres and scaffolds was maintained as proven by significant reduction in viable cells after treatment with PLGA microspheres as well as with the gelatin constructs (p < 0.001). The drug-polymer conjugate can be used as a controlled drug delivery system in a biocompatible scaffold that could potentially promote preservation of soft tissue contour.
Collapse
Affiliation(s)
- Alicia J Defail
- Department of Bioengineering, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
| | | | | | | | | |
Collapse
|
12
|
Epstein JB, Cabay RJ, Glick M. Oral malignancies in HIV disease: Changes in disease presentation, increasing understanding of molecular pathogenesis, and current management. ACTA ACUST UNITED AC 2005; 100:571-8. [PMID: 16243242 DOI: 10.1016/j.tripleo.2005.01.015] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2004] [Accepted: 01/10/2005] [Indexed: 11/19/2022]
Abstract
Infection with human immunodeficiency virus (HIV) and progression to acquired immune deficiency syndrome (AIDS) are associated with a vide variety of morbidities. Local and systemic diseases can develop in association with HIV infection and may manifest themselves as malignancies of the oropharynx. Advances in HIV management, fueled by increasing understanding of molecular pathogenesis, have resulted in marked changes in the prevalence of oral malignant disease. This paper discusses recent trends in the presentation and treatment of malignancies related to HIV and AIDS with an emphasis on malignancies seen in the oral cavity.
Collapse
MESH Headings
- Animals
- Antiretroviral Therapy, Highly Active
- Carcinoma, Squamous Cell/complications
- Carcinoma, Squamous Cell/epidemiology
- Carcinoma, Squamous Cell/therapy
- Carcinoma, Squamous Cell/virology
- DNA, Viral/analysis
- Developed Countries
- HIV Infections/complications
- HIV Infections/drug therapy
- Herpesvirus 4, Human/isolation & purification
- Humans
- Lymphoma, AIDS-Related/complications
- Lymphoma, AIDS-Related/epidemiology
- Lymphoma, AIDS-Related/therapy
- Mouth Neoplasms/complications
- Mouth Neoplasms/epidemiology
- Prevalence
- Sarcoma, Kaposi/complications
- Sarcoma, Kaposi/epidemiology
- Sarcoma, Kaposi/therapy
- United States/epidemiology
Collapse
Affiliation(s)
- Joel B Epstein
- Department of Oral Medicine and Diagnostic Sciences, College of Dentistry, Chicago Cancer Center, University of Illinois at Chicago, IL 60612USA.
| | | | | |
Collapse
|
13
|
Gambassi G, Semeraro R, Suma V, Sebastio A, Incalzi RA. Aggressive Behavior of Classical Kaposi's Sarcoma and Coexistence With Angiosarcoma. J Gerontol A Biol Sci Med Sci 2005; 60:520-3. [PMID: 15933395 DOI: 10.1093/gerona/60.4.520] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
UNLABELLED An 82-year-old Caucasian man presented with initially asymptomatic livid red plaques on the plantar surface of the feet that become confluent and evolved into invasively growing nodules accompanied by massive edema. Histology allowed a diagnosis of the classical form of Kaposi's sarcoma; the serology test result for HIV was negative, whereas the associated human herpes virus type 8 was detected by polymerase chain reaction on the skin sample. Over the subsequent 6 months, skin lesions become vegetative and partially necrotic, and extended to the hands and eyelids. Chemotherapy with vinblastine appeared to stabilize the cutaneous disease, but the patient developed a massive gastrointestinal hemorrhage secondary to dissemination to the stomach. Twelve months after the onset of the disease, vegetative and easily bleeding lesions progressively occluded the mouth of the patient: histological features were consistent with a low-grade angiosarcoma distinct from that of Kaposi's sarcoma. The patient could not chew and swallow anymore; he was put on an artificial nutrition but died shortly thereafter. This case illustrates that, even in its classical form, Kaposi's sarcoma may be a malignant, rapidly progressing tumor. LEARNING POINTS a) The extent and rate of spread of initial skin lesions should be considered to be early signs of aggressive dissemination, even in the absence of other variables (i.e., histological pattern, human herpes virus type 8 positive mononuclear cells) associated with progression of the disease. b) An endoscopy may be useful given the high prevalence of gastrointestinal involvement. c) When classical Kaposi's sarcoma displays aggressive behavior a second, primary malignant tumor arising from the vascular tissue should be investigated. TAKE-HOME MESSAGE Even in its classical form, Kaposi's sarcoma may be a malignant, rapidly progressing tumor with visceral involvement; also, a second malignancy may occur in nearly one patient of four. Because localized skin lesions can regress completely with radiotherapy, watchful waiting is probably inappropriate in most cases.
Collapse
Affiliation(s)
- Giovanni Gambassi
- Centro Medicina Invecchiamento, Dipartimento di Scienze Gerontologiche, Geriatriche e Fisiatriche, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli, 8, 00168 Rome, Italy.
| | | | | | | | | |
Collapse
|
14
|
Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U. Therapeutic approaches to AIDS-related malignancies. Oncogene 2003; 22:6646-59. [PMID: 14528290 DOI: 10.1038/sj.onc.1206771] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The introduction of highly active antiretroviral therapy (HAART) has changed dramatically the landscape of HIV disease. Deaths from AIDS-related diseases have been reduced by 75% since protease inhibitor therapy and combination antiretroviral therapy came into use in late 1995. While KS is declining, the situation for non-Hodgkin's lymphoma is more complex with a reduced incidence of primary central nervous system lymphoma, but a relatively stability in the number of patients developing systemic NHL. AIDS related NHL appears not to be markedly decreased by the introduction of HAART and it is the greatest therapeutic challenge in the area of AIDS oncology. The emphasis has now shifted to cure while maintaining vigilance regarding the unique vulnerability of HIV-infected hosts. Furthermore, also for the prolongation of the survival expectancy of these patients, other non AIDS-defining tumors, such as Hodgkin's disease, anal and head and neck, lung and testicular cancer, and melanoma have been recently reported with increased frequency in patients with HIV infection.
Collapse
Affiliation(s)
- Massimiliano Berretta
- Division of Medical Oncology A, Centro di Riferimento Oncologico, National Cancer Institute, Via Pedemontana Occ.Le 12, Aviano (PN) 33081, Italy
| | | | | | | | | | | |
Collapse
|